Open access
Open access
Powered by Google Translator Translator

TB/Non-TB Mycobacterial Infections

USPSTF Statement | Asymptomatic adults at increased risk should be screened for latent TB

5 May, 2023 | 15:34h | UTC

Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statement – JAMA

Evidence Report: Screening for Latent Tuberculosis Infection in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA

Editorials:

Screening for Latent Tuberculosis Infection Among Non–US-Born Adults in the US: A Path Toward Elimination – JAMA

Screening for Latent Tuberculosis Infection – JAMA Network Open

JAMA Patient Page: Screening for Latent Tuberculosis

Author Interview: USPSTF Recommendation: Screening for Latent Tuberculosis Infection in Adults

 


Brief Review | Management of latent tuberculosis infection

5 May, 2023 | 15:32h | UTC

Management of Latent Tuberculosis Infection – JAMA (free for a limited period)

 


Review | Transforming tuberculosis diagnosis

5 May, 2023 | 15:18h | UTC

Transforming tuberculosis diagnosis – Nature Microbiology (if the link is paywalled, try this one)

 

Commentary on Twitter

 


Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people

26 Apr, 2023 | 14:11h | UTC

Post-tuberculosis lung impairment: systematic review and meta-analysis of spirometry data from 14 621 people – European Respiratory Review

 


WHO releases first-ever Standard on universal access to rapid TB diagnostics

24 Apr, 2023 | 14:04h | UTC

News Release: WHO releases first-ever Standard on universal access to rapid TB diagnostics – World Health Organization

WHO Standard: Universal access to rapid tuberculosis diagnostics – World Health Organization

 


Improving cascade outcomes for active TB | A global systematic review and meta-analysis of TB interventions

30 Mar, 2023 | 14:17h | UTC

Improving cascade outcomes for active TB: A global systematic review and meta-analysis of TB interventions – PLOS Medicine

 


M-A | The natural history of untreated pulmonary tuberculosis in adults

28 Mar, 2023 | 14:42h | UTC

The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis – The Lancet Respiratory Medicine (free registration required)

 

Commentary from the author on Twitter

 


SR | Post-tuberculosis sequelae in children and adolescents

27 Mar, 2023 | 13:16h | UTC

Post-tuberculosis sequelae in children and adolescents: a systematic review – The Lancet Infectious Diseases (free registration required)

 


M-A | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine

27 Mar, 2023 | 13:14h | UTC

Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis – The Lancet Respiratory Medicine (free registration required)

Invited Commentary: Shorter regimens for tuberculosis preventive treatment: piecing together the global implementation jigsaw – The Lancet Respiratory Medicine (free registration required)

 

Commentary on Twitter

 


M-A | Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis

23 Mar, 2023 | 12:50h | UTC

Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis – The Lancet Child & Adolescent Health

News Release: New Algorithms Could Improve Pediatric Tuberculosis Diagnosis – Yale School of Public Health

 

Commentary from the author on Twitter (thread – click for more)

 


Review | Evidence-based approach to diagnosis and management of abdominal tuberculosis

16 Mar, 2023 | 13:17h | UTC

Evidence-based approach to diagnosis and management of abdominal tuberculosis – Indian Journal of Gastroenterology (if the link is paywalled, try this one)

 

Commentary from the author on Twitter

 


RCT | An initial 8-week bedaquiline-linezolid regimen shows promise for the treatment of rifampin-susceptible tuberculosis

22 Feb, 2023 | 12:50h | UTC

Summary: This randomized trial compared a standard 6-month rifampin-based tuberculosis treatment to a strategy that involved shorter initial treatment with extended therapy for persistent disease, monitoring, and retreatment for relapse. The results showed that the strategy involving an 8-week bedaquiline-linezolid regimen was noninferior to standard treatment for clinical outcomes. The experimental strategy was associated with a shorter total duration of treatment with no evident safety concerns.

Article: Treatment Strategy for Rifampin-Susceptible Tuberculosis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Shorter drug regimen shows promise in TB trial – CIDRAP

 


Review | Contemporary pharmacotherapies for nontuberculosis mycobacterial infections

17 Feb, 2023 | 13:03h | UTC

Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review – Infectious Diseases and Therapy

 


Review | Female genital tuberculosis

16 Feb, 2023 | 14:42h | UTC

Female Genital Tuberculosis – Open Forum Infectious Diseases

 


M-A | Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection

24 Jan, 2023 | 14:25h | UTC

Assessing the diagnostic performance of new commercial IGRAs for Mycobacterium tuberculosis infection: a systematic review and meta-analysis – Clinical Infectious Diseases

 

Commentary on Twitter

 


Brief review and algorithm | Management of latent tuberculosis infection

23 Jan, 2023 | 13:35h | UTC

Management of Latent Tuberculosis Infection – JAMA (free for a limited period)

 


Consensus statement | Use of a 4-month treatment regimen for drug susceptible TB in children with uncomplicated disease

18 Jan, 2023 | 14:25h | UTC

Consensus statement on the use of a four-month treatment regimen for drug susceptible tuberculosis in children (< 10 years of age) with uncomplicated disease – Australian Government Department of Health and Aged Care

 


RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis

12 Jan, 2023 | 13:27h | UTC

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine

Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP

 


WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update

12 Jan, 2023 | 13:30h | UTC

WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update – World Health Organization

See also:

WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment

WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection, 2021 update

WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents

 


Collection of Cochrane evidence on diagnosing tuberculosis.

1 Dec, 2022 | 13:56h | UTC

Collection of Cochrane evidence on diagnosing tuberculosis – Cochrane Library

 


WHO Global tuberculosis report 2022.

29 Nov, 2022 | 14:25h | UTC

Global tuberculosis report 2022 – World Health Organization

News Release: Tuberculosis deaths and disease increase during the COVID-19 pandemic – World Health Organization

Video Summary: WHO Global Tuberculosis Report 2022: Key findings and messages – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


RCT | Evaluation of two short, standardized regimens for the treatment of rifampicin-resistant tuberculosis.

15 Nov, 2022 | 12:57h | UTC

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial – The Lancet

Commentary: 

Shorter treatment effective for drug-resistant tuberculosis – University College London

Shorter Treatment Regimen for Drug-Resistant TB is More Effective – Health Policy Watch

 


RCT | Efficacy of 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide for treatment of fluoroquinolone-sensitive MDR-TB.

9 Nov, 2022 | 12:11h | UTC

9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea – The Lancet (link to abstract – $ for full-text)

 


RCT | A digital medication event reminder may improve quality of life and reduce costs in patients with tuberculosis.

1 Nov, 2022 | 11:48h | UTC

Effect of Digital Medication Event Reminder and Monitor-Observed Therapy vs Standard Directly Observed Therapy on Health-Related Quality of Life and Catastrophic Costs in Patients With Tuberculosis: A Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

Commentaries:

Digital Medication Device Improves Quality of Life, Reduces Costs for TB Patients – HCP Live

Digital Medication Monitor Linked to Better HRQOL, Lower Costs for Tuberculosis – AJMC

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1570442333686042628

 


Systematic Review | Global frequency and clinical features of stroke in patients with tuberculous meningitis.

6 Sep, 2022 | 14:19h | UTC

Global Frequency and Clinical Features of Stroke in Patients With Tuberculous Meningitis: A Systematic Review – JAMA Network Open

 


Stay Updated in Your Specialty

No spam, just news.